Highlights

  • Botanix Pharmaceuticals (ASX:BOT) is commercialising Sofdra for primary axillary hyperhidrosis.
  • The company reported increasing prescription volumes during FY2026.
  • Sofdra received US Food and Drug Administration approval in 2024 for excessive underarm sweating.
  • Prescription growth, cost management and cash requirements remain key areas to monitor.

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology-focused biotechnology company developing commercial opportunities around Sofdra (sofpironium) gel. The product received US Food and Drug Administration approval in June 2024 for primary axillary hyperhidrosis, a condition involving excessive underarm sweating.

The company’s strategy is centred on converting regulatory approval into prescription-based commercial activity. Hyperhidrosis affects millions of people and has historically been managed through a range of treatments, creating Demand for prescription Options designed specifically for the condition.

Commercial Rollout Progress

Botanix has continued building its Sofdra commercial platform through prescription growth and distribution activities. For the fourth quarter of financial year 2026, the company reported 33,358 Sofdra prescriptions, representing a 25% increase from the previous quarter.

The company reported unaudited net Revenue of US$10.1 million for the quarter and highlighted a monthly prescription record during June 2026. Earlier FY2026 updates also showed continued growth in prescriptions and revenue as the product launch progressed.

Botanix has focused on improving commercial efficiency through changes to its sales structure and reducing costs associated with territories that were not meeting expectations.

Building a Prescription-Based Business

Sofdra is designed as a self-applied topical treatment, supporting a prescription and fulfilment model rather than a procedure-based approach. The company has also developed digital prescribing and fulfilment capabilities to support patient access.

A key part of the commercial strategy is increasing awareness among healthcare providers and patients while maintaining access through reimbursement channels. Long-term performance depends on continued prescription adoption and efficient commercial execution.

Financial and Operational Considerations

While Sofdra sales have expanded, Botanix continues to manage the financial requirements of a commercial-stage healthcare company. The company reported cash of approximately US$36.6 million at 30 June 2026, while full-year FY2026 operating cash outflows were approximately US$64.3 million.

The company remains focused on improving operating efficiency and moving towards a more sustainable financial position. Future Capital requirements may depend on prescription growth, revenue progression and operating expenses.

Key Insights

Botanix has moved from product approval into a commercialisation phase with Sofdra as its primary focus. The company’s next stage will depend on expanding prescription activity, maintaining commercial efficiency and demonstrating progress towards a sustainable operating model.